

# Pfizer Inc.

**37.55** Usd  
**-2.47%**

ISIN: US7170811035  
Ticker: PFE

Sector: Pharmaceuticals  
Stock exchange: NYSE

Market capitalization: 208 billion

**Key Metrics:**

Performance YTD: -4.16%  
Estimated 2020 P/E: 12.55

Earning per share: 2.9  
Price to book: 3.4

Net Debt: 41 billion  
Return on Equity: 0.13

## Fundamental analysis summary

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. Pfizer revenues have been constant over the past four years, ranging around 52 billion. Net income and EBITDA have also remained steady, only FCF decreased over the past four years. The same story applies for the four last quarters. Pfizer did not suffer much from COVID-19 but has not shown any sign of growth. The company revenue in Q3 was down 4% YoY but Biopharma sector was up 4%.

## Technical analysis summary

Pfizer's stock price was on an uptrend since 2009 until 2018. Since then, it has seemed to lack momentum to push the stock further up. The recent 7% gain made on its COVID-19 vaccine has already been absorbed by the market. On the same day, the CEO sold for 5 million USD worth of shares. RSI is in between regular bounds.

## Chart - Year To Date

